Linarin

Linarin is a glycosylated flavonoid (acacetin-7-O-rutinoside) that exerts anxiolytic, anti-inflammatory, and neuroprotective effects by inhibiting NF-κB and MAPK signaling, modulating acetylcholinesterase activity, and binding the sulfonylurea receptor-1 (SUR1) to reduce oxidative neuronal stress. All documented pharmacological evidence derives from preclinical in vitro and animal models—including 50 mg/kg oral dosing reversing cytokine-driven lethality in mice—with no human clinical trial data currently available to confirm efficacy or safe dosing in humans.

Origin & History

Linarin is a naturally occurring flavonoid glycoside biosynthesized in several plant species across temperate and subtropical regions, most notably in Valeriana officinalis (common valerian, native to Europe and Asia) and Lycium chinense/barbarum (wolfberry, native to East Asia). It is also found in Chrysanthemum indicum, Buddleja species, and Cirsium japonicum, distributed across Mediterranean, Central Asian, and East Asian floras. The compound is not commercially cultivated in isolation but is extracted via standard phytochemical fractionation from dried roots, bark, or aerial parts of these source plants.

Historical & Cultural Context

Linarin was first isolated and chemically characterized from Linaria vulgaris (common toadflax, family Plantaginaceae) in the mid-twentieth century, from which its name derives, and has since been identified across dozens of plant genera used in Ayurvedic, Traditional Chinese, and European herbal medicine. In Traditional Chinese Medicine, its source plant Lycium chinense root bark (Di Gu Pi) has been prescribed for over two millennia to clear heat, cool blood, and manage febrile conditions associated with what modern medicine recognizes as inflammatory and metabolic disorders including diabetes. Valeriana officinalis, another linarin-containing plant, has been documented in European herbalism since at least the ancient Greeks (Dioscorides, 1st century CE) and was widely employed in medieval European and later Eclectic American medicine for nervousness, insomnia, and hysteria, with valerian preparations appearing in the British Pharmacopoeia through the 20th century. The specific pharmacological role of linarin within these multi-constituent traditional preparations was not distinguishable from whole-plant activity until modern phytochemical fractionation techniques enabled its isolation and individual bioassay in the late 20th and early 21st centuries.

Health Benefits

- **Anti-Inflammatory Activity**: Linarin suppresses LPS-induced production of nitric oxide, TNF-α, IL-1β, IL-6, and PGE2 in RAW264.7 macrophages at concentrations of 2.5–20 μg/mL by co-inhibiting NF-κB nuclear translocation and MAPK (ERK, JNK, p38) phosphorylation, also reducing vascular permeability and tissue edema in rodent models.
- **Hepatoprotection**: At 50 mg/kg in galactosamine/LPS-induced acute liver failure mouse models, linarin attenuated hepatocyte apoptosis by suppressing the TLR4/IRAK cascade, downregulating caspase-3 and cytochrome c release, and upregulating anti-apoptotic Bcl-xL and p-STAT3/STAT3 ratios.
- **Neuroprotection and Anxiolytic Potential**: Linarin binds the sulfonylurea receptor-1 (SUR1) to mitigate ATP-depletion-induced oxidative stress in neurons, and its 4'-methoxyl group and 7-O-rutinoside moiety inhibit acetylcholinesterase (AChE), potentially preserving cholinergic neurotransmission relevant to anxiety and cognitive decline.
- **Insulin Resistance and Antidiabetic Effects**: In palmitate-treated HepG2 hepatocytes and high-fat diet obese mouse models, linarin improved glucose uptake and insulin sensitivity by targeting c-FOS/ARG2 signaling, reducing ARG2 expression and hepatic inflammation, and lowering body weight and fat mass accumulation.
- **Anticancer Properties**: Preclinical data demonstrate linarin induces apoptosis, oxidative stress, and genotoxic effects while inhibiting proliferation and migration/invasion in lung, prostate, glioma, and brain cancer cell lines, suggesting broad cytotoxic activity not yet characterized in human tissue.
- **Cardiovascular and Vascular Effects**: Linarin modulates Akt signaling and suppresses iNOS/COX-2 expression in human umbilical vein endothelial cells (HUVECs), reducing endothelial inflammatory activation that underlies atherosclerotic plaque formation.
- **Sedative and Sleep-Supporting Context**: As a constituent of Valeriana officinalis, linarin contributes to the sedative pharmacology of valerian root preparations, though its isolated contribution to GABAergic or adenosine receptor modulation relative to other valerian constituents (valerenic acid, isovaltrate) has not been fully delineated.

How It Works

Linarin's anti-inflammatory mechanism centers on dual inhibition of NF-κB (preventing IκB degradation and p65 nuclear translocation) and the MAPK cascade (blocking phosphorylation of ERK1/2, JNK, and p38), thereby suppressing transcription of iNOS, COX-2, and proinflammatory cytokine genes in macrophages and hepatocytes. Its hepatoprotective effect is mediated through interference with TLR4/IRAK1/4 signaling, reduction of mitochondrial apoptotic signaling (↓cytochrome c release, ↓caspase-3 activation), upregulation of Bcl-xL, and activation of the JAK/STAT3 survival pathway. Neuroprotective activity involves direct binding to SUR1 on neurons and astrocytes, attenuating ATP-sensitive potassium channel dysregulation during ischemic or oxidative stress, while the aglycone acacetin backbone and 7-O-rutinoside substituent sterically inhibit acetylcholinesterase at the active site gorge. Antidiabetic effects are mechanistically linked to transcriptional suppression of c-FOS and ARG2, two nodes implicated in hepatic insulin resistance and inflammatory lipid metabolism, improving downstream insulin receptor substrate (IRS-1) phosphorylation and GLUT2-mediated glucose uptake.

Scientific Research

The entire body of evidence for linarin is preclinical, comprising in vitro cell-based assays and small animal in vivo studies with no registered or published human clinical trials identified as of 2024. In vitro studies have used standardized macrophage (RAW264.7), hepatocyte (HepG2), endothelial (HUVEC), and cancer cell line models at well-defined concentrations (5–160 μM), providing mechanistic clarity but limited translational certainty. Animal studies have employed mouse and rat models of acute liver failure, high-fat diet obesity, and neurological injury, with linarin administered orally at approximately 50 mg/kg, yielding statistically significant improvements in survival, cytokine profiles, glucose tolerance, and histopathological endpoints—though sample sizes are typically small and not always reported. The evidence base is insufficient to establish human efficacy, optimal bioavailable dose, pharmacokinetic parameters, or comparative effectiveness versus approved therapeutics, and the compound should be regarded as investigational.

Clinical Summary

No human clinical trials evaluating isolated linarin have been conducted or reported in the peer-reviewed literature to date, meaning there are no clinical effect sizes, patient populations, primary endpoints, or safety outcomes from which to draw translatable conclusions. Relevant evidence is entirely extrapolated from preclinical models: 50 mg/kg oral linarin reversed GalN/LPS-induced lethality and normalized TNF-α/IL-6 in mice, and high-fat diet obese mice showed improved glucose tolerance, reduced insulin resistance index, and decreased fat mass following linarin treatment. These animal-derived findings, while pharmacologically coherent and mechanistically well-characterized, cannot reliably predict effective or safe human doses due to unknown oral bioavailability, first-pass metabolism, and species-specific pharmacokinetic differences. Confidence in linarin as a clinically actionable intervention is currently very low, and its use in humans should be considered experimental pending Phase I/II trial data.

Nutritional Profile

Linarin is a pure flavonoid glycoside molecule (molecular formula C₂₈H₃₂O₁₄, molecular weight 592.54 g/mol) and does not contribute macronutrients, vitamins, or minerals as a dietary constituent. Its structure consists of the flavone aglycone acacetin (5,7-dihydroxy-4'-methoxyflavone) glycosylated at the C-7 hydroxyl position with the disaccharide rutinose (6-O-α-L-rhamnopyranosyl-β-D-glucopyranoside). Phytochemically, it belongs to the flavone subclass of flavonoids, sharing structural and bioactivity overlap with apigenin, acacetin, and luteolin. Bioavailability is expected to be moderate and dependent on gut microbiome-mediated deglycosylation to release the acacetin aglycone, which is more lipophilic (logP ~2.8) and membrane-permeable; no quantitative human absorption studies (Cmax, Tmax, AUC) have been published for linarin specifically.

Preparation & Dosage

- **Isolated Compound (Research Grade)**: Used at 5–160 μM in in vitro studies; 50 mg/kg oral gavage in mouse models—no direct human dose equivalent established
- **Valerian Root Extracts (Indirect Source)**: Standardized valerian preparations (0.3–0.8% valerenic acids) containing unquantified linarin; typical anxiolytic/sleep doses of 300–600 mg dried root extract taken 30–60 minutes before sleep
- **Lycii Cortex (Di Gu Pi) Decoctions (Indirect Source)**: Traditional TCM preparations use 6–15 g dried root bark per decoction, with linarin present among multiple glycosides; concentration not standardized
- **Standardization**: No commercial supplement is currently standardized to a defined linarin percentage; linarin content in source herbs varies by plant part, harvest season, and extraction solvent (methanol/ethanol most efficient)
- **Bioavailability Consideration**: As a flavonoid glycoside, linarin likely undergoes intestinal deglycosylation to acacetin prior to absorption, but oral bioavailability data in humans are unavailable; lipophilic delivery vehicles or piperine co-administration are theoretical enhancers
- **Timing**: No clinically validated timing recommendations exist; preclinical sedative data from valerian context suggest evening administration for CNS-related applications

Synergy & Pairings

Linarin from Valeriana officinalis is likely synergistic with valerenic acid and isovaltrate—the primary sesquiterpenoids in valerian—since valerenic acid modulates GABA-A receptor activity while linarin contributes AChE inhibition and SUR1 binding, potentially creating complementary anxiolytic and neuroprotective coverage across distinct receptor systems. In the context of metabolic syndrome, preclinical logic supports combining linarin-containing lycium bark extract with berberine, which independently activates AMPK and suppresses hepatic gluconeogenesis via a distinct pathway from linarin's c-FOS/ARG2 target, producing additive insulin-sensitizing effects observed in HFD models using multi-herb TCM formulas. For anti-inflammatory stacking, co-administration with curcumin (NF-κB inhibitor via IKK suppression) and quercetin (MAPK modulator) could theoretically produce additive pathway inhibition, though no direct in vivo linarin combination studies have been published.

Safety & Interactions

No adverse effects have been reported in preclinical models at in vitro concentrations up to 160 μM or oral doses of 50 mg/kg in rodents, suggesting low acute toxicity in animal systems, but human safety data are entirely absent and no maximum tolerated dose, NOAEL, or LOAEL has been established for human exposure to isolated linarin. Because linarin inhibits NF-κB, COX-2, and inflammatory pathways, theoretical pharmacodynamic interactions exist with NSAIDs, corticosteroids, and immunosuppressive drugs where additive immunosuppression could increase infection risk or impair wound healing. The parent herb Valeriana officinalis has documented sedative interactions with benzodiazepines, barbiturates, and CNS depressants that may be partially attributable to flavonoid constituents including linarin, warranting caution in co-administration. No pregnancy or lactation safety data exist for isolated linarin; given the general precautionary principle applied to uncharacterized phytochemicals and the lack of teratogenicity or embryotoxicity studies, use during pregnancy or breastfeeding cannot be recommended.